"The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names."
"The investment logic is exposure to biotech innovation without the full binary risk profile of early-stage drug development. These companies already have approved franchises, recurring revenue, and balance sheet capacity to acquire smaller peers."
"IBB has returned about 45% over the past year and carries $8.12 billion in net assets, making it one of the deepest and most liquid biotech funds available."
"The tradeoff is concentration at the top. When a single large holding stumbles on a pipeline setback or a patent headline, the fund feels it is more than an equal-weight alternative would be."
The biotech sector has seen a resurgence due to drug approvals, obesity treatments, oncology pipelines, and increased merger activity. The iShares Biotechnology ETF serves as a large-cap anchor, focusing on profitable companies rather than early-stage risks. It holds major positions in Gilead Sciences, Amgen, Vertex Pharmaceuticals, and Regeneron, which together make up a significant portion of the fund. With a 45% return over the past year and $8.12 billion in assets, it is a leading biotech fund, though it may be too concentrated for those seeking small-cap exposure.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]